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BACKGROUND: The decision whether to treat patients with non-metastatic colon cancer with adjuvant chemotherapy is determined by
clinical staging, frequently resulting in over or undertreatment.
METHODS: Gene expression data and clinical information from 232 stage 1–4 colon cancer patients were analysed to identify
expression patterns predictive of recurrence. The signature was evaluated on an independent series of 60 stage 2 and 3 patients.
Multivariate analyses were performed to assess the clinical utility of the assay.
RESULTS: A 163-probe signature was able to stratify patients into high- and low-risk groups for disease-free survival (DFS) in both the
training and validation series (stage 2: Pp0.031, stage 3: Pp0.057) and for disease-specific survival in the training series (stage 2: P¼0.01,
stage 3: P¼0.0017). Multivariate analysis showed the classifier to be associated with approximately three- to fourfold increased risk of
recurrence.
CONCLUSIONS: The prognostic gene expression signature is able to stratify stage 2 and 3 colon cancer patients into groups with significant
differences in 5-year DFS, information that may ultimately reduce deaths from colon cancer. Further validation work is required and at
this stage the assay is available for evaluation at www.ChipDX.com.
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Each year, tumours of the colon are responsible for 655000 deaths
globally (2009). In the USA, it is the fifth most common type of
cancer, with an estimated 106100 new cases annually (Jemal et al,
2008). Fortunately, most patients are diagnosed in the early
stages of the disease (i.e., stage 1 or 2), when surgical resection is
usually curative. If the cancer has spread to regional lymph nodes
(stage 3), surgery and adjuvant chemotherapy (ACTx) represent
the current standard of care (Obrand and Gordon, 1997;
Markowitz and Bertagnolli, 2009).
The use of staging as the primary means of determining ACTx
eligibility results in undertreatment of some stage 2 patients, who
generally do not receive chemotherapy, but experience disease
recurrence in approximately 20% of cases (Quasar Collaborative
et al, 2007). Improved methods for identifying stage 2 patients at
high risk of recurrence, based on the unique characteristics of each
individual tumour may result in thousands of lives saved each
year. Conversely, studies have shown that practise of treating all
stage 3 patients with ACTx results in overtreatment of a substantial
portion of cases (Sargent et al, 2009). Although chemotherapy has
been shown to improve survival for patients with stage 3 cancers,
surgery alone is curative for 43% of individuals in this group.
Techniques for identifying those stage 3 patients who are at low
risk of disease recurrence after surgery may spare these individuals
from the cost, time and toxicity associated with chemotherapy.
The use of gene expression profiling to develop new tools for
identifying patients at high risk of disease recurrence has been
explored by a number of groups. Smith et al (2009) refined a
metastasis-associated gene expression profile, originally identified
in a mouse model of colorectal cancer, to a 34-gene signature
associated with metastasis and death in human patients. In stage
3 patients, the hazard ratio for recurrence was 4.7 (95% CI: 1.57–
14.05). Jorissen et al (2009) used the gene expression difference
between stage 1 and stage 4 tumours to create a 128-gene classifier
that stratified stage 2 and stage 3 patients into groups with
significant differences in outcome. The treatment-adjusted hazard
ratio of their classifier, when applied to stage 3 patients, was 2.9
(95% CI: 1.1–7.6), although a result was not generated for 16% of
all patients tested, limiting the clinical utility of this assay.
In the present study, gene expression data from stage 1–4 colon
cancer patients (Jorissen et al, 2009) were analysed using Cox
survival models to identify genes associated with outcome, over
and above the level of traditional prognostic factors such as age,
grade and staging (Cox, 1972). A predictive algorithm was trained
using all genes identified by this selection process and evaluated
on an independent series of 60 stage 2 and 3 colon cancer patients
(Smith et al, 2009).
The algorithm has been implemented into the ChipDX online
analysis system (http://www.ChipDX.com), compatible with the
widely available Affymetrix GeneChip platform. The prognostic
signature and online analysis system may allow clinicians to
incorporate gene expression profiling into the management of
colon cancer patients, without the time, logistics and expense
involved in sending biopsy material to an external reference
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slaboratory. Analysis of genomic data using the ChipDX Colon
Cancer Module is currently free for evaluation purposes and non-
diagnostic use.
PATIENTS AND METHODS
Patients and gene expression data
A database of clinical and gene expression data was compiled from
a previously described patient series (Smith et al, 2009) to identify
individual genes with expression patterns significantly associated
with prognosis and train an algorithm to predict colon cancer
recurrence. This database was comprised of 232 whole-genome
Affymetrix U133 Plus 2.0 profiles, generated from fresh-frozen
biopsies from colon cancer patients diagnosed with stage 1–4
disease (NCBI GEO: GSE17538). These patients were treated at
either the Vanderbilt Medical Centre (Nashville, TN, USA) or the
H Lee Moffitt Cancer Center (Tampa, FL, USA) and are described
in detail in the original publication. Data were available for age at
diagnosis, gender, tumour grade, AJCC stage, and disease-free
survival (DFS) and disease-specific survival (DSS).
To objectively assess the significance of the prognostic algorithm
developed, an independent validation series of 60 Affymetrix U133
Plus 2.0 profiles from stage 2 and 3 colon cancer patients from
another previously published study was used (Jorissen et al, 2009).
This clinical validation series (GEO ID: GSE14333) was generated
from tumour biopsies obtained from consecutive colon cancer
patients treated at Westmead Hospital (Westmead, Australia), The
Peter MacCallum Cancer Centre and the Royal Melbourne Hospital
(both Melbourne, Australia). All patients were untreated before
surgery and data were available for age at diagnosis, gender, tumour
grade, AJCC stage and DFS. A summary of training and validation
series demographics is shown in Table 1.
As the reproducibility of gene expression data can be influenced
by a number of technical factors such as reagent or chip
batches and scanning equipment settings, an additional series of
Affymetrix U133 Plus 2.0 hybridizations were analysed to assess
the stability of the prognostic signature between analysis sites
(Bowtell, 1999; Mutter et al, 2004). In all, 120 GeneChip CEL files,
representing four pools of cell-line RNA, hybridised five times in
six different laboratories, were used for this analysis. These data
were part of the multi-centre Microarray Quality Control study
(MAQC), (GEO ID: GSE5350) (Shi et al, 2006).
Data processing and quality control
All Affymetrix CEL files were processed using MAS5 normalisation
and background correction. Probes with low intensity (o100)
were excluded and each chip was median centred, based on the
expression of the internal 100-probe ‘reference set’, a series of
probes selected by Affymetrix based on their low variation between
multiple tissue types. Although the authors of the original studies
reportedly examined the quality of their hybridizations before
analysis, all genomic data were re-analyzed using the ChipDX
Quality Module, which was specifically designed for diagnostic
applications. This multi-step quality system evaluates factors
such as nonspecific background binding, normalisation factors,
signal-to-noise ratios and replicate probe variation. GeneChips
flagged by the ChipDX Quality Module were excluded from the
classifier evaluation analyses. See Supplementary Information for
more information.
Prognostic gene selection and algorithm training
A modified version of the method described by Bair and Tibshirani
(2004) was used to develop and train a predictive algorithm
capable of stratifying patients into categories corresponding to low
or high risk of disease recurrence (Figure 1). This approach uses
CPH models to relate survival time to two ‘metagene’ expression
levels. These ‘metagenes’ are the first two principle component
linear combinations of the corresponding genes found to be
significantly associated with recurrence, independent to clinical
covariates. The prognostic significance of each gene was assessed
using multivariate CPH regression models that included age at
diagnosis, tumour grade and clinical staging. In this study, genes
with patterns of expression that were significant at Po0.002 were
Table 1 Patient demographics of the colon cancer series used for gene
selection, algorithm training and independent validation
Training
series
Independent validation
series
NCBI GEO ID GSE17538 GSE14333
Contributing institutes Vanderbilt Medical Center
(Nashville, TN) & H. Lee
Moffit Cancer Center
(Tampa, FL, USA)
The Peter MacCallum Cancer
Centre, Westmead Hospital,
& Royal Melbourne Hospital
(Australia)
Number of samples 232 60
Age (years),
mean±s.d.
64±13.4 68±13.7
Stage 1, n (%) 28 (12%) —
Stage 2, n (%) 72 (31%) 33 (55%)
Stage 3, n (%) 76 (33%) 27 (45%)
Stage 4, n (%) 56 (24%) —
Gender: female, n (%) 110 (47%) 28 (47%)
Gender: male, n (%) 122 (53%) 32 (53%)
Adjuvant chemotherapy — 22 (37%)
Adjuvant radiotherapy — 1 (2%)
Median follow-up/
survival (months),
(range)
30 (0–210) 37 (2–85)
No. recurrences, n (%) 55 (23%) 16 (17%)
No. deaths, n (%) 93 (40%) NA
Abbreviation: NA¼not applicable.
Cox regression
analysis of gene
expression data and
clinical information
Algorithm training and
cross validation
(N=232)
Application of rank-
based classifier to
independent
validation series
(N=60)
Conversion of
expression data to
percentile rank values
3
2
4
1
Figure 1 Overview of the analysis performed to develop and validate a
novel prognostic gene expression signature for stage 2 and 3 colon cancer.
After selection of genes significantly associated with outcome in
log-intensity scale, data were converted to percent-rank values and used
to re-train the predictive metagene algorithm.
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sused to compute the principle components and regression coeffi-
cients (weights).
To apply the classifier on data from a patient whose gene
expression profile is described by a vector ‘x’ of log expression
levels, the two principle components are computed by combining x
with the weights of each linear combination. The weighted average
of these two principle component values is then calculated,
resulting in a value referred to as the ‘prognostic index’. A high
prognostic index corresponds to an increased hazard of colon
cancer recurrence. The classification threshold was set based on
the 50th percentile of training series indices, which were calculated
using leave-one-out cross validation (LOOCV).
After completing this process on the 232-sample training series,
expression data for genes selected in 20% or more of the cross-
validation rounds were converted to percentile-rank values (range
0.00–100.00) and used to retrain the predictive algorithm.
Training-series risk-group predictions from both log-intensity
and percentile-rank versions of the algorithm were compared.
Finally, the rank-based prognostic algorithm was applied to data
from the independent validation series of patients with stage 2 or 3
colon cancer.
Statistical analysis of risk-group predictions
Kaplan–Meier analysis and log-rank testing was used to
evaluate the differences between the predicted risk groups in the
training series for 5-year DFS and DSS The independent validation
series was evaluated for 5-year DFS only as DSS data was not
available. Multivariate Cox proportional hazards (CPH) analysis
was performed to determine the independence of the prognostic
signature in the presence of clinical covariates. For all tests,
P-values o0.05 were considered significant.
Gene expression analysis was performed using R (http://www.
r-project.org), Bioconductor (Gentleman et al, 2004) and BRB
ArrayTools (Simon and Lam). Statistical analysis of the prognostic
index and risk-group predictions was carried out using MedCalc
(MedCalc Inc., Mariakerke, Belgium). A custom R-script was
created to encapsulate the diagnostic algorithm and was incorpo-
rated into to the ChipDX online analysis system; developed with R,
Bioconductor, Microsoft ASP.NET and SQL Server (Microsoft
Corporation, WA, USA).
RESULTS
Identification of recurrence-associated gene expression
patterns
Multivariate analysis of the 232-sample stage 1–4 training series
successfully identified a set of 163 probes, significantly associated
with colon cancer recurrence, independent to age, grade and stage.
An annotated list of the 163 probes and Cox P-values is provided
in Supplementary Information. The gene set was compared with
prognostic colon cancer signatures published by Smith et al
(34 genes) and Jorissen et al (128 genes). No overlap was found
between all three signatures, or between the Smith and Jorissen
signatures. In all, seven genes were found in common between the
Jorissen signature and the 163 probe set identified in this study;
AKAP12, DCBLD2, FN1, SPARC, SPP1, THBS2 and VCAN. The
hypergeometric probability of this overlap occurring by chance
is o1.40 10
 7.
To explore the biological functions of the genes selected to
form the prognostic signature, Ingenuity Pathway Analysis soft-
ware was used (http://www.ingenuity.com). A significant overlap
was detected with several relevant gene families, including
colon cancer progression (e.g., FN1, IGBP3, PLAUR and TIMP1;
P¼0.00052), tumour cell apoptosis (e.g., BID, TNFRSF21,
PHLDA1 and NOTCH1; P¼1.46 10
–6) and cell proliferation
(e.g., CTGF, SPP1, FOLR1 and SPARC). Enrichment of genes from
the IGF-1 signalling and VDR/RXR activation canonical pathways
(P¼7.82 10
 4 and P¼3.85 10
 3 respectively) was also found.
These molecular pathways have been implicated in colon
cancer development and progression (Khandwala et al, 2000;
Wactawski-Wende et al, 2006).
A gene expression ‘heatmap’ of the 163-probe signature in the
training series is shown in Figure 2, in which genes (columns) are
arranged by hierarchical clustering and patients (rows) are ordered
according to their prognostic index. The relationship between gene
expression and disease recurrence can be observed in the pattern
of upregulation and downregulation formed by this arrangement,
with higher expression of those genes on the left of the heatmap
associated with poor prognosis and vice versa. An increasing
frequency of recurrence events (indicated to the right of the
heatmap) can be observed as the prognostic index increases from
 2.0 to þ2.0.
Analysis of cross-validated training series risk-group
predictions
In order to reflect the intended use of the assay, risk-group
predictions for the subset of the training series with stage 2 or
3 colon cancer (n¼144) were compared using Kaplan–Meier
analysis for DFS and DSS. These predictions were generated using
LOOCV, as part of the gene selection and algorithm training
process, in order to minimise over fitting of the data (Simon,
2005). Log rank testing revealed a significant difference between
the high- and low-risk groups for both DFS (P¼0.0008, HR:
4.08 95% CI: 1.99–8.34) and DSS (Po0.0001, HR 19.59 95% CI:
8.33–46.07), and also for stratification by risk group and clinical
staging (Figure 3). For comparison purposes, Kaplan–Meier
analysis of these patients stratified by staging was performed,
however the result was not statistically significant for either DFS
(P¼0.75) or DSS (P¼0.30).
No differences in risk-group predictions were observed between
versions of the 163-probe algorithm trained on log intensity or
percentile-rank expression data. Therefore, the performance of the
predictive algorithm was not affected by this data transformation step.
Analysis of independent clinical validation series
The trained 163-probe algorithm was then applied to data from an
independent series of 33 stage 2 and 27 stage 3 colon cancer patients,
not involved in the gene selection or algorithm development process.
In all, 35 (58%) of these patients were classified as low risk (i.e.,
prognostic index o50th percentile of cross-validated training series
indices;  0.104). Kaplan–Meier analysis and log rank testing of the
two risk groups, containing both stage 2 and 3 patients, revealed a
significant difference in 5-year DFS (P¼0.021, HR: 3.19 95% CI:
1.18–8.63), as shown in Figure 3.
Kaplan–Meier analysis of risk groups stratified by gene
expression risk group and clinical staging was then performed,
resulting in a significant difference in DFS for stage 2 patients
(P¼0.0031) and approaching significance for stage 3 patients
(P¼0.057), as shown in Table 2. Notably, no low-risk stage 2
patient from this series experienced disease recurrence for (up to)
5 years.
Multivariate analysis of gene expression risk groups
To evaluate the significance of the 163-gene classifier in a
multivariate setting, CPH analysis was performed on stage 2 and
3 patients from both training and validation series, including all
available clinical covariates (Table 3). For the LOOCV-analyzed
training series, this investigation revealed the gene expression-
based risk group assignment to be the strongest predictor of
both DFS (P¼0.0018, HR 4.23, 95% CI 1.72–10.39) and DSS
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gender, stage and grade.
CPH analysis of the independent validation series included age,
gender, stage, ACTx/ARTx status and gene expression risk group.
The gene expression classifier was observed to be a strong
predictor of recurrence, with a hazard ratio of 3.04 (95% CI:
0.96–9.69), although it did not achieve independent statistical
significance in this model (P¼0.061). This is possibly because of
the limited size of the validation series or the impact of adjuvant
therapy on DFS.
Disease-free survival
Training series (n=144) Validation series (n=60)
Disease-free survival Disease-specific survival
P=0.0005 P=0.0009 P=0.0008
%
100
80
60
40
20
0
Time (months)
Stage 2: low risk: 32, high risk: 37
Stage 3: low risk: 35, high risk: 40
Stage 2: low risk: 31, high risk: 35
Stage 3: low risk: 31, high risk: 38
Stage 2: low risk: 19, high risk: 14
Stage 3: low risk: 16, high risk: 11
0 1 02 03 04 05 06 0
%
100
80
60
40
20
0
Time (months)
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%
80
60
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20
100
0
Time (months)
0 1 02 03 04 05 06 0
Figure 3 Kaplan–Meier analysis of stage 2 and 3 colon cancer patients stratified by clinical staging and the 163-gene prognostic signature. Risk-group
predictions for those patients who were part of the training series (n¼144) were determined by cross-validation analysis. The final 163-gene classifier was
then applied to the independent analysis series (n¼60) of patients, who were not involved in the gene selection or algorithm development process. P-values
generated by the log rank test.
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Figure 2 Gene expression heatmap of the 163-probe colon cancer prognosis signature in a subset of the stage 1–4 training series. Patients without
recurrence and less than 3-years follow-up, or recurrence events 410 years, have been excluded. Rows indicate patients (ordered by prognostic index),
columns indicate probes (ordered by hierarchically clustering using average linkage similarity). Red colour indicates high gene expression, green colour
indicates low gene expression (log2 scale). Recurrence events are indicated to the right of the heatmap. Yellow horizontal line corresponds to the
classification threshold, determined during algorithm training. The colour reproduction of this figure is available on the html full text version of the manuscript.
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sAnalysis of replicate hybridizations performed at multiple
laboratories
Replicate hybridizations of four RNA pools were analysed to
determine the impact interlaboratory variation on the 163-probe
prognostic index. In all, five replicate Affymetrix hybridizations of
four samples, performed at six separate locations were processed.
All 120 samples were classified as ‘high risk’ and no significant
difference was observed between the replicate hybridizations
performed at any given site (P40.05). Standard deviation of the
mean site indices was sample A: 0.032, sample B: 0.051, sample C:
0.029 and sample D: 0.034. The mean s.d. (0.037) represents 1.1% of
the prognostic index range observed in the algorithm training series
and is used to compute a 95% confidence interval for prognostic
index calculations performed in the ChipDX online analysis system.
DISCUSSION
As the use of chemotherapy for patients with stage 2 and 3 cancer
remains controversial (Quasar Collaborative et al, 2007), there is a
need for improved methods of risk assessment. In this study,
multivariate survival models were applied to clinical and gene
expression data to identify a prognostic signature for stage 2 and
3 colon cancer. This was used to create a robust diagnostic tool
that may ultimately assist clinicians in tailoring personalised
treatment options, in conjunction with the clinical staging system.
The ‘meta-gene’ classification algorithm was developed from a
multi-centre series of stage 1–4 colon cancer patients and then
independently validated on a separate series of stage 2 and 3 colon
cancer patients. In the case of patients with stage 2 disease, the
assay is able to identify those who are at low risk of disease
recurrence; that is, 89% RFS in the training series and 100% RFS
in the validation series, for up to 5 years following diagnosis. By
comparison, high-risk stage 2 patients experience a 24–27% lower
rate RFS, suggesting that adjuvant therapies should be considered
for patients assigned to this risk group. Stratification of stage 2
patients also corresponded to a significant difference in DSS in the
training series, confirming the clinical significance of the assay.
Patients diagnosed with stage 3 colon cancer are commonly
treated with ACTx, yet relapse is still observed in approximately
40% of cases (Andre et al, 2004). Genomic stratification of stage 3
patients in this study resulted in groups with significant
differences in RFS, with those patients classified as high risk
experiencing an extremely poor 5-year RFS rate of 43% (training
series) and 26% (validation series). As such, a patient with stage 3
disease and the high-risk gene expression signature may benefit
from a more aggressive treatment regimen, possibly including
targeted or experimental therapies, such as bevacizumab or
panitumumab (Hurwitz et al, 2004; Seront et al, 2010).
The signature developed in this study differs from previous
groups in several ways. First, it was developed exclusively using
a training series of gene expression and clinical data derived
from human colon tumours, representing all major stages of
progression. Tumours of the rectum were intentionally excluded
as they are increasingly recognised as a distinct category with a
different origins and treatment options (Konishi et al, 1999). Each
gene in the signature is individually associated with outcome
independent to traditional prognostic variables. The algorithm
trained on these data uses robust gene expression rank values,
rather than log-scale intensities which are more susceptible to inter
and intralaboratory technical variation. Finally, the prognostic
index is a continuous variable, positively correlated with increased
risk of colon cancer recurrence and capable of stratifying patients
into risk groups that are statistically and clinically significant, for
up to 5 years following diagnosis.
The 163-probe prognostic algorithm is available for evaluation
at www.ChipDX.com, which includes an automated GeneChip
quality control and result reporting system, designed for the
Affymetrix platform. Further validation studies are required to
assess the significance of the classifier in additional cohorts of
Table 2 Disease-free survival rates for the training and validation series, disease-specific survival rates (maximum) for training series patients (stage2
and 3) and validation series patients
Series Clinical Stage Risk group Percent of series 5-year DFS (%) Log-rank P-value 5-year DSS Log rank P-value
Training 2 Low 31 89 0.0002 100% 0.010
High 35 63 70%
3 Low 16 87 0.0016 96% 0.0017
High 18 43 61%
Validation 2 Low 32 100 0.031
NA
High 23 73
3 Low 27 75 0.057
High 18 26
Abbreviation: NA¼not available.
Table 3 Multivariate Cox proportional hazards regression of the training & independent validation series (stage 2 and 3 patients) using clinical factors and
gene expression risk groups
Training series (DFS) Training series (DSS) Validation series (DFS)
Covariate P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI)
Age 0.38 0.99 (0.96–1.01) 0.38 1.01 (0.98–1.05) 0.31 0.98 (0.93–1.02)
Gender (M) 0.59 0.81 (0.38–1.74) 0.97 0.98 (0.40–2.42) 0.22 0.49 (0.16–1.52)
Grade 0.96 1.02 (0.50–2.05) 0.95 1.02 (0.43–2.43) — —
Stage (3) 0.07 2.04 (0.95–4.41) 0.28 1.66 (0.65–4.22 0.0021 9.23 (2.26–37.70)
Adjuvant chemotherapy — — 0.22 0.43 (0.12–1.62)
Adjuvant radiotherapy — — 0.32 3.35 (0.31–36.095)
Gene expression risk group (high risk) 0.0018 4.22 (1.72–10.39) 0.004 19.13 (2.59–141.54) 0.061 3.042 (0.96–9.69)
Abbreviations: CI¼confidence interval; DFS¼disease-free survival; DSS¼disease-specific survival.
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scolon cancer patients and to investigate stability on tissues
preserved by paraffin fixation or other mediums. Ultimately, the
assay developed herein may be used to more accurately select
individual patients for potentially life-saving adjuvant therapy,
while sparing those who are predicted to have a favourable
prognosis.
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